A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial

References

• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383(9914):333–341.
   PubMed Web of Science ®Google Scholar
• Kernan WH, Ovbiagele B, Black HR, et al. AHA/ASA guideline: guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45:2160–2236.
   PubMed Web of Science ®Google Scholar
• Ogawa A, III-2. The Japan Stroke Society. Committee on Guidelines for the Management of Stroke. Japanese guidelines for the management of stroke 2015. Tokyo: Kyowa Kikaku; 2015. p. 101–112.
   Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.
   PubMed Web of Science ®Google Scholar
• Fiolaki A, Katsanos AH, Kyritsis AP, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis. J Neurol Sci. 2017;376:112–116.
   PubMed Web of Science ®Google Scholar
• Yi X, Lin J, Zhou Q, et al. Clopidogrel resistance increases rate of recurrent stroke and other vascular events in Chinese population. J Stroke Cerebrovasc Dis. 2016;25(5):1222–1228.
   PubMed Web of Science ®Google Scholar
• Gengo FM, Rainka M, Robson M, et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol. 2008;48(3):335–343.
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195–198.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430–2435.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436.
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84(2):236–242.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38(4):402–408.
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347–361.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in myocardial infarction 38. Circulation. 2008;118(16):1626–1636.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–2560.
   PubMed Web of Science ®Google Scholar
• Stroke Guideline Committee of the Japan Stroke Society. Japanese guidelines for the management of stroke. Tokyo: Kyowa Kikaku; 2015.
   Google Scholar
• Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Bourguet N, Boulay-Moine D, et al. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost. 2012;107(2):388–395.
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008;39(6):1827–1833.
   PubMed Web of Science ®Google Scholar
• Fukuuchi Y, Tohgi H, Okudera T, et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis. 2008;25(1–2):40–49.
   PubMed Web of Science ®Google Scholar
• Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78(7):1684–1692.
   PubMed Web of Science ®Google Scholar
• Isshiki T, Kimura T, Ogawa H, et al. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J. 2014;78(12):2926–2934.
   PubMed Web of Science ®Google Scholar
• Umemura K, Ikeda Y, Kondo K. Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects. Drug Metab Pharmacokinet. 2016;31(4):285–291.
   PubMed Web of Science ®Google Scholar